FDA Approves EYLEA HD for RVO and Monthly Dosing Across Indications
A fresh FDA nod gives retina specialists more room to flex their dosing strategy. It’s another busy day at the…
FDA Grants Priority Review to Eylea HD for Macular Edema Following RVO
QUASAR Phase III study data show higher-dose aflibercept could reduce injection frequency for retinal vein occlusion patients. Bayer (Leverkusen, Germany)…
latest posts